Fig. 2 | Scientific Reports

Fig. 2

From: Tanshinone IIA suppresses the proliferation and fibrosis of mesangial cell in diabetic nephropathy though WTAP-mediated m6A methylation

Fig. 2The alternative text for this image may have been generated using AI.

Tan IIA treatment regulated WTAP-mediated m6A modification. (A) Dot blot assay was performed to assess the total m6A level in each group (n = 3); (B) RT-qPCR was performed to analyze the mRNA levels of METTL3, METTL14, RBM15, VIRMA, WTAP, ZC3H13, FTO, and ALKBH5 in each group (n = 3); (C) The 3D structure of the binding complex of WTAP with Tan IIA and the detail binding mode of the complex. The backbone of the protein was rendered in tube. Compound is rendered by green and the OGT is shown in blue sticks. Yellow and ray dash represents hydrogen bond. Data are expressed as the mean ± SD. Tan IIA, Tanshinone IIA; WTAP, Wilms tumor 1-associating protein; m6A, N6-methyladenosine; RT-qPCR, reverse transcription-polymerase chain reaction; METTL, methyltransferase; RBM15, RNA binding motif protein 15; VIRMA, vir-like m(6)A methyltransferase-associated protein; ZC3H13, zinc finger CCCH-type containing 13; FTO, alpha‐ketoglutarate dependent dioxygenase; ALKBH5, AlkB homolog 5.

Back to article page